| Literature DB >> 18513425 |
Pia Johansson1, Siv Sadigh, Per Tillgren, Clas Rehnberg.
Abstract
BACKGROUND: Elderly injuries are a recognized public health concern and are due to two factors; osteoporosis and accidental falls. Several osteoporosis pharmaceuticals are considered cost-effective, but intervention programs aiming at preventing falls should also be subjected to economic evaluations. This study presents a cost-effectiveness analysis of a community-based elderly safety promotion program.Entities:
Year: 2008 PMID: 18513425 PMCID: PMC2440733 DOI: 10.1186/1478-7547-6-11
Source DB: PubMed Journal: Cost Eff Resour Alloc ISSN: 1478-7547
Figure 1Overview of Markov model.
Figure 2Evaluation design.
Model data. Costs in SEK 2004 (95% confidence intervals in parenthesis).
| Annual risk of hip fracture | men 65–79 y | 0.0049 | Effect evaluation |
| men 80+ y | 0.0175 | ||
| women 65–79 y | 0.0053 | ||
| women 80+ y | 0.0261 | ||
| Death risks after hip fracture | 1st year after hip fracture: | pers.com. F. Borgström, Stockholm Health Economics, 2006-11-17 | |
| Death risks | age- and gender-specific | National Death Register | |
| Health care costs | initial cost | 110,364 (105,123 – 115,221) | Stockholm County Council healthcare data base |
| annual cost | 12,590 (11,141 – 14,243) | ||
| Community care | annual cost | 38,200 (26,304 – 55,711) | [21] |
| Pharmaceuticals | annual cost | 1,552 (1,360 – 1,753) | [21] |
| Informal care | annual cost | 3,223 (1,954 – 5,524) | [21] |
| QoL reduction from hip fracture | annual | 0.17 | [21] |
| Average QoL | men 65–69 y | 0.78 | [22] |
| men 70–79 y | 0.76 | ||
| men 80+ y | 0.68 | ||
| women 65–69 y | 0.75 | ||
| women 70–79 y | 0.66 | ||
| women 80+ y | 0.57 | ||
Model estimates. Costs in SEK 2004.
| Men, aged 65–79 y | ||||||||
| 1st year | 466,630 | 177,121 | 9,730 | 256,387 | 23,392 | 3.54 | 20.48 | 12.51 |
| avoided 1st year | 30,160 | 13,256 | 568 | 14,974 | 1,363 | 6.74 | 16.31 | 9.42 |
| 9,162 | ||||||||
| Men, aged 80+ y | ||||||||
| 1st year | 296,974 | 140,625 | 5,242 | 138,488 | 12,620 | 1.72 | 11.21 | 8.55 |
| avoided 1st year | 19,918 | 10,118 | 330 | 8,684 | 787 | 3.03 | 9.89 | 7.41 |
| 4,911 | ||||||||
| Women, aged 65–79 y | ||||||||
| 1st year | 608,211 | 207,675 | 13,474 | 354,703 | 32,358 | 3.93 | 17.11 | 10.10 |
| avoided 1st year | 60,516 | 24,246 | 1,220 | 32,121 | 2,929 | 6.63 | 13.89 | 7.81 |
| 12,255 | ||||||||
| Women, aged 80+ y | ||||||||
| 1st year | 370,170 | 156,440 | 7,181 | 189,304 | 17,245 | 1.85 | 9.71 | 7.30 |
| avoided 1st year | 39,846 | 18,491 | 720 | 18,901 | 1,734 | 2.97 | 8.85 | 6.57 |
| 6,462 | ||||||||
*survivors at the age of 100 years are assumed to be dead at the age of 100.
§ discounted 3%.
Summary of the cost-effectiveness analysis. Costs in SEK 2004.
| Program costs | ||
| Project wage costs | 1,783,889 | |
| Other wage costs | 1,920,119 | |
| Volunteers | 76,025 | |
| Running costs | 308,959 | |
| Other costs | 1,527,409 | |
| Participants' costs | 834,748 | |
| Costs avoided | ||
| Medical care | 2,350,551 | |
| Pharmaceuticals | 140,257 | |
| Community care | 3,694,309 | |
| Informal care | 337,017 | |
| Health effects | ||
| Life-years saved (YLS)* | 42.23 | |
| QALYs | 35.16 | |
*undiscounted
Sensitivity analysis results. Costs in SEK 2004.
| Base case | 6,522 134 | -70,985 | 35 | <0 |
| Model parameters | ||||
| A. Fracture risk [39] | 6,479,356 | -28,207 | 35 | <0 |
| A. Fracture risk doubled | 5,978,641 | 472,508 | 33 | 14,327 |
| B. Mortality risk [40] | 7,401,024 | -949,875 | 29 | <0 |
| C. Medical treatment costs [21] | 11,793,758 | -5,342,609 | 35 | <0 |
| C. Medical treatment costs, average difference | 6,420,258 | 30,891 | 35 | 879 |
| 1 year before and 2 years after hip fracture | ||||
| D. 2nd and following year costs [21] | 6,709,090 | -257,941 | 35 | <0 |
| E. Non-market productivity incl. [41] | 6,789,172 | -338,023 | 35 | <0 |
| E. Costs in added life-years [14] | 447,200 | 6,003,949 | 35 | 170,907 |
| F. Alternative QoL weights [42] | 6,522,134 | -70,989 | 48 | <0 |
| G. Discount rate 0% | 7,535,125 | -1,083,976 | 45 | <0 |
| G. Discount rate 5% | 5,986,099 | 465,050 | 30 | 15,313 |
| H. Mortality and hip fracture risks [39,40] | 7,385,325 | -934,176 | 29 | <0 |
| I. No costs or QoL effects after 1st year | 1,935,529 | 4,515,620 | 22 | 202,041 |
| J. Another disease; fracture risks doubled, no costs or QoL effects after 1st year | 1,730,899 | 4,720,250 | 21 | 228,805 |
| Program specific | ||||
| Program costs +25% | 6,522,134 | 1,541,798 | 35 | 43,888 |
| Program effectiveness: lowest | 2,712,870 | 3,738,279 | 21 | 178,013 |
| Program effectiveness: highest | 12,534,792 | -6,083,643 | 67 | <0 |
Figure 3Bootstrap simulation of model estimated differences in cost and QALYs. Costs in SEK 2004.